Summit Therapeutics SMMT reported fourth-quarter 2024 loss per share of 8 cents, in line with the Zacks Consensus Estimate. In the year-ago period, the company incurred a loss of 5 cents per share.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results